Inanc, SenizKeles, DidemEskiizmir, GorkemBasbinar, YaseminOktay, Gulgun2023-06-162023-06-1620192149-71092149-6498https://doi.org/10.32448/entupdates.569464https://hdl.handle.net/20.500.14365/2486Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line. Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method. Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells. Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the drug repositioning of the treatment of oral cavity cancer.eninfo:eu-repo/semantics/openAccessMetforminDichloroacetatedrug combinationsoral cavitycancerTumor-GrowthCancerDeathProliferationHif-1-AlphaArticle10.32448/entupdates.569464